Trillium Therapeutics Receives a Buy from Cowen & Co.

By Ryan Adsit

Cowen & Co. analyst Boris Peaker reiterated a Buy rating on Trillium Therapeutics (NASDAQ: TRIL) yesterday. The company’s shares closed yesterday at $14.60.

Peaker commented:

“This morning TRIL announced that TTI-621 has advanced into Phase Ib expansion.”

According to, Peaker is a 5-star analyst with an average return of 7.8% and a 40.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Corvus Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Trillium Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.

The company has a one year high of $17.70 and a one year low of $6.62. Currently, Trillium Therapeutics has an average volume of 93.44K.

Trillium Therapeutics, Inc. operates as a biotechnology company, which is engaged in the business of developing stem cell-based therapeutics through partnerships with research institutions or technology transfer organizations. It operates through single segment include Research and Development of Immunotherapy Drugs for the treatment of cancer. The company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. Trillium Therapeutics was founded on March 31, 2004 and is headquartered in Toronto, Canada.